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Abstract
Background: Etiological epidemiology and diagnosis are important issues in adult community-acquired pneumonia
(CAP), and identifying pathogens based on patient clinical features is especially a challenge. CAP-associated main
pathogens in adults include viruses as well as bacteria. However, large-scale epidemiological investigations of adult
viral CAP in China are still lacking. In this study, we analyzed the etiology of adult CAP in Beijing, China and
constructed diagnostic models based on combinations of patient clinical factors.
Methods: A multicenter cohort was established with 500 adult CAP outpatients enrolled in Beijing between
November 2010 to October 2011. Multiplex and quantitative real-time fluorescence PCR were used to detect 15
respiratory viruses and mycoplasma pneumoniae, respectively. Bacteria were detected with culture and enzyme
immunoassay of the Streptococcus pneumoniae urinary antigen. Univariate analysis, multivariate analysis,
discriminatory analysis and Receiver Operating Characteristic (ROC) curves were used to build predictive models for
etiological diagnosis of adult CAP.
Results: Pathogens were detected in 54.2% (271/500) of study patients. Viruses accounted for 36.4% (182/500),
mycoplasma pneumoniae for 18.0% (90/500) and bacteria for 14.4% (72/500) of the cases. In 182 of the patients
with viruses, 219 virus strains were detected, including 166 single and 53 mixed viral infections. Influenza A virus
represented the greatest proportion with 42.0% (92/219) and 9.1% (20/219) in single and mixed viral infections,
respectively. Factors selected for the predictive etiological diagnostic model of viral CAP included cough, dyspnea,
absence of chest pain and white blood cell count (4.0-10.0) × 109/L, and those of mycoplasma pneumoniae CAP
were being younger than 45 years old and the absence of a coexisting disease. However, these models showed
low accuracy levels for etiological diagnosis (areas under ROC curve for virus and mycoplasma pneumoniae were
both 0.61, P < 0.05).
Conclusions: Greater consideration should be given to viral and mycoplasma pneumoniae infections in adult CAP
outpatients. While predictive etiological diagnostic models of viral and mycoplasma pneumoniae based on
combinations of demographic and clinical factors may provide indications of etiology, diagnostic confirmation of
CAP remains dependent on laboratory pathogen test results.
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Background
Community-acquired pneumonia (CAP) has a major
impact on public health and results in more than 10
million visits to physicians and 600,000 hospitalizations
each year in the USA [1], where it is the seventh leading
cause of death, and its economic burden has been esti-
mated to be more than $17 billion annually [2,3]. Etio-
logical epidemiology and diagnosis are important issues
in adult CAP, with particular challenges in identifying the
causative pathogens based on patient clinical features.
Studies conducted prior to the year 2000 showed that
the predominant pathogen of CAP was Streptococcus
pneumoniae, which accounted for approximately two-
thirds of the detected CAP pathogens [4-6]. Later, atyp-
ical pathogens began showing increasing trends among
CAP cases [7]. In the last two decades, with the rapid
development of molecular diagnostic techniques and the
outbreak of severe acute respiratory syndrome (SARS)
coronavirus, avian influenza A (H5N1) virus and the 2009
pandemic influenza A (H1N1) virus, viral CAP has gar-
nered more attention. Shin [8] pointed out that if clini-
cians do not consider a viral etiology in patients with
CAP, they would be unlikely to consider investigations
to diagnose respiratory viruses, which would result in
the inappropriate use of antibiotics, missed opportunity
to consider antiviral treatment and failure to institute
appropriate infection control measures. Ruuskanen et al.
[9] also stressed the importance of viral CAP and the ur-
gent need to gather epidemiological data on etiological
pathogens from developing countries. At present, China
still lacks large-scale epidemiological investigations of
adult viral CAP. Furthermore, antibiotic resistance is a
serious issue in China, as 24.9% of the S. pneumoniae
has been found to be resistant to penicillin and 87.5% to
macrolide [10], while the macrolide resistance rate of
mycoplasma pneumoniae (M. pneumoniae, MP) in adults
has been estimated at 69% [11]. Accordingly, under-
estimation of the prevalence of viral CAP and utilization
of inappropriate treatment may increase the spread of
antibiotic resistance.
Based on the considerations above, we investigated the
etiology of adult CAP in Beijing, China from November
2010 to October 2011. Furthermore, combinations of
clinical factors of this population were analyzed in order
to build etiological diagnostic models to predict the viral
or M. pneumoniae sources of infection.
Methods
Study patients
Five hundred adult outpatients were enrolled between
November 2010 to October 2011 from 12 hospitals, in-
cluding 8 teaching hospitals and 4 secondary hospitals,
in Beijing, China. These 12 hospitals serve approximately
20 million outpatients annually. Our study subjects were
from the outpatient department of infectious diseases or
respiratory diseases of these hospitals, at which at least
20,000 CAP patients are seen annually.
The inclusion criteria were based on the following: 1)
patients were at least 18 years old; 2) site-of-care decisions
for outpatients were made according to the Infectious
Diseases Society of America/American Thoracic Society
(IDSA/ATS) guidelines on the management of CAP in
adults in 2007 [12]; 3) CAP was defined by a new infil-
trate on a chest X-ray examined by two radiologists and
the presence of one of the following clinical characteristics:
new cough or aggravated cough with or without sputum
production; fever (> 37.8°C) or hypothermia (< 35.6°C),
leukocytosis (> 10 × 109/L) or leukopenia (< 4 × 109/L)
[13]; 4) patients agreed to participate in this investiga-
tion and accepted the laboratory tests and etiological
examination voluntarily. Patients were excluded if they
were HIV infected or under an immunosuppressed state,
had clinical symptoms for more than 1 week from the
time of onset, were pregnant or in the lactation period,
were hospitalized within the prior 90 days (hospital stay
longer than 2 days), lived in a nursing home or re-
habilitation hospital, or had been previously treated with
antivirals.
Data collection
Data on demographic factors (sex, age, smoking, coexisting
disease and antibiotic pretreatment), clinical symptoms and
signs (fever, body temperature, max temperature, heart rate,
respiratory rate, systolic pressure ≤ 90 mmHg, cough, ex-
pectoration, dyspnea, chest pain, diarrhea, vomiting, dizzi-
ness, headache, moist rales and dry rales) and laboratory
test results [white blood cell (WBC) counts, neutrophil,
lymphocyte, hematocrit, platelets, alanine aminotransferase,
aspartate aminotransferase, blood creatinine, blood sodium,
pH, PaO2, erythrocyte sedimentation rate, C-reactive pro-
tein, prothrombin time and activated partial thromboplas-
tin time] were collected using data abstraction forms for
patients meeting the inclusion criteria. This process was ac-
companied by stringent quality controls, including training
specific doctors for recording of information; selecting
study patients strictly in accordance with inclusion and
exclusion criteria; using standardized abstraction forms
to guide data collection in case of conflicting, ambiguous
and missing information; defining the coexisting disease,
including tumor, coronary heart disease, heart failure, ce-
rebrovascular disease, chronic nephropathy, chronic hepa-
topathy, diabetes mellitus, CAP hospitalization within the
prior one year, chronic obstructive pulmonary and auto-
immune disease based on specialist opinion; ensuring
laboratory tests were obtained from a nationally accredited
laboratory; and establishing a monitoring system for the
collection of information.
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Sample collection
A single throat swab, using Sterile Rayon Swabs (167KS01,
Guangzhou, China), was collected from each study patient
before receiving antivirals or antibiotic drugs. The swab
was immediately placed in a virus transport media tube
(167KS01, Guangzhou, China). Each sample was frozen
at −80°C within 24 h until analyzed.
Sputum or blood was obtained for bacterial culture be-
fore antibiotic therapy, while blood culture was usually
performed when the patient temperature was higher than
38.5°C. Patients were instructed to produce a deep ex-
pectoration after gargle into a sterile, dry, impermeable,
non-absorbent container within 2 h before the test. Ten
milliliters of blood was obtained and inoculated into
two culture bottles (5 mL was inoculated into an aerobic
bottle and 5 mL into an anaerobic bottle). Thirty minutes
later, an additional 10 mL of blood was obtained from a dif-
ferent site, and the procedure was repeated. We obtained
altogether 369 sputum samples and 85 sets of blood sam-
ples. Middle clean urine samples for S. pneumoniae testing
were obtained 1 day after enrollment for all study patients.
Detection of viruses and M. pneumoniae
Multiplex PCR (Neuro-Hemin Biotech Co., Ltd, Hangzhou,
China) was used to detect 15 common respiratory viruses
by throat swabs, including influenza A virus (Flu A) , influ-
enza B virus (Flu B), parainfluenza virus types 1, 2, 3, and 4
(PIV1, 2, 3, 4), respiratory syncytial virus types A and B
(RSVA and RSVB), adenovirus (AdV), human coronavirus
229E/NL63, OC43 (CoV 229E/NL63, OC43), rhinovirus
HRV A/B/C (hRV), human bocavirus 1/2/3/4 (hBoV),
human metapneumovirus (hMPV) and enterovirus (EnV).
Quantitative real-time fluorescence PCR was used for
detection of M. pneumoniae in throat swabs. Detections of
viruses and M. pneumoniae were performed in the Clinical
Microbiology Department in the Beijing Chao-Yang Hos-
pital of Capital Medical University.
DNA and RNA were extracted from samples using
the QIAamp DNA Mini kit (Cat. No.51306, Qiagen,
Hilden, Germany) and QIAamp Viral RNA Mini Kit
(Cat. No.52906, Qiagen), following the manufacturer’s
instructions. The extracted RNA was used as template
to perform the reverse transcriptase polymerase chain
reaction (RT-PCR) with a commercial kit (Fermentas,
Shenzhen, China) as follows. Total RNA (8 μl), random
hexamers (1 μl of 0.2 μg/μl) and DEPC-treated water (3 μl)
were added to an RT tube on ice, incubated at 80°C for
3 min and then chilled on ice again for 2 min. There-
after, 5× RT buffer (4 μl), 10 mm dNTP (2 μl), RNase in-
hibitor (1 μl of 20 U/μl) and reverse transcriptase (1 μl of
200 U/μl) were added to the tube, which was then incu-
bated at 37°C for 90 min, followed by 94°C for 2 min. After
chilling on ice for a further 2 min, the complementary
DNA (cDNA) generated from the reverse transcription was
stored at −20°C until ready for use. The PCR amplification
system included the cDNA template (3 μl), 5× RV Primer
(4 μl), 8-Mop Solution (3 μl) and 2× Multiplex Master Mix
(10 μl), and the conditions were: 94°C for 15 min, followed
by 40cycles of 94°C for 0.5 min, 60°C for 1.5 min and 72°C
for 1.5 min, with extension at 72°C for 10 min. The product
was stored at 4°C until used. All PCR products, markers
and negative control were analyzed by electrophoresis in
1% agarose gels stained with ethidium bromide and visu-
alized using the Molecular Imager Gel Doc XR System
(Bio-Rad 170–8170, Hercules, CA, USA). The Quanti-
tative Diagnosis Kit for M. pneumoniae DNA (PCR Fluor-
escence Probing, Da An Co., Ltd, Guangzhou, China) was
used for M. pneumoniae detection with the following PCR
amplification system: DNA template (2 μl), MP PCR reac-
tion mix (40 μl) and Taq enzyme (3 μl). The PCR reaction
was carried out using a quantitative PCR instrument
(ABI Prism 7500, USA) with the following conditions:
93°C for 2 min, followed by 10 cycles of 93°C for 45 sec
and 55°C for 1 min, and another 30 cycles of 93°C for
0.5 min and 55°C for 10 min.
Detection of bacteria
All sputum samples were examined by microscopy, and
representative sputum originating from the lower respira-
tory tract was defined as that containing > 25 granulocytes
and < 10 epithelial cells per field of view under a low
power microscope. The standard four zoning line method
was used for semi-quantitative culture. Conventional
blood culture was processed in an automated system.
S. pneumoniae urine antigen was detected using an en-
zyme immunoassay. Detection of bacteria was performed
at each hospital laboratory.
Statistical analysis
Statistical analysis was performed using SPSS statistical
software version 16.0 (SPSS Inc., Chicago, IL, USA). Discrete
variables were expressed as counts (percentage) and con-
tinuous variables as means ± SD or median (interquartile
range). Frequency comparisons were made with the chi-
square test. Two-group comparisons of normally distrib-
uted data were performed with the independent samples
t-test. For multi-group comparisons, one-way analysis
of variance (ANOVA) with the least-squares difference
post hoc test was applied. For data not normally distrib-
uted, the Mann–Whitney U test was used if only two
groups were compared, and Kruskal-Wallis one-way
ANOVA was used if more than two groups were being
compared. Variables with P values less than 0.2 in uni-
variate analysis were used in multivariate logistic regres-
sion analysis. The removal probability for multivariate
stepwise logistic regression analysis was 0.1. Discriminatory
analysis and Receiver Operating Characteristic (ROC) curves
were used to build and assess the predictive etiological
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diagnostic models. A probability of P < 0.05 was consid-
ered to be statistically significant. For convenience in
the analysis, the following pathogens were grouped as
follows: CoV 229E/NL63, CoV OC43 (CoV); PIV1, 2, 3,
4 (PIV); RSVA and RSVB (RSV).
Ethics statement
The study protocol was in accordance with the Declaration
of Helsinki and was approved by the ethics committees of
the 12 participating hospitals (Peking University People’s
Hospital, Beijing Chao-Yang Hospital, Beijing Haidian Hos-
pital, YanTai Yu Huangding Hospital, Luhe Teaching Hos-
pital of the Capital Medical University, WangJing Hospital
of China Academy of Chinese Medical Sciences, Peking
Union Medical College Hospital, China-Japan Friendship
Hospital, Beijing Friendship Hospital, Beijing Pinggu Hos-
pital, Huairou the First Hospital and Air Force General
Hospital, PLA) in the study. The nature, purpose and po-
tential risks of this study were carefully explained to each
subject prior to enrollment. Written informed consent
was obtained from all enrolled patients.
Results
Pathogen distribution
Pathogens were detected in 54.2% (271/500) of study
patients, and the mixed infection ratio of different patho-
gens was 13.4% (67/500). In our study, viruses accounted
for 36.4% (182/500), M. pneumoniae for 18.0% (90/500)
and bacteria for only 14.4% (72/500) of the cases (Figure 1).
Based on the detected pathogens, the 500 enrolled pa-
tients were divided into five groups as shown in Tables 1,
2, and 3.
Distribution of detected virus
We detected 219 virus strains in the 182 patients with
viruses, including 166 single and 53 mixed viral infections.
Among the single and mixed viral infections, the re-
spective percentages of each virus were as follows: Flu
A, 42.0% (92/219) and 9.1% (20/219); hRV, 9.6% (21/219)
and 1.8% (4/219); AdV, 9.1% (20/219) and 2.3% (5/219);
PIV, 7.8% (17/219) and 6.8% (15/219); hMPV, 3.2% (7/219)
and 1.4% (3/219); RSV, 1.8% (4/219) and 1.4% (3/219);
EnV, 1.4% (3/219) and 0%; CoV, 0.9% (2/219) and 0.9%
(2/219); Flu B, 0% and 0.5% (1/219).
Monthly distribution of detected viruses
Flu A infections increased gradually in November 2010,
peaked in January 2011 and declined by March 2011 in
China. RSV also emerged in November 2010 but could
not be detected from February 2011. AdV and hMPV were
both detected from January 2011, peaking in February and
March, respectively. Infections of hMPV lasted about four
months and that of AdV six months. The seasonal distri-
butions of PIV and hRV were not significantly different.
Patient demographic and clinical factors
We collected data from the 500 patients, including demo-
graphic characteristics, symptoms, signs and laboratory
test results, as shown in Tables 1, 2, and 3. By comparing
symptoms, physical examinations and laboratory test re-
sults of monomicrobial infections, we found that CAP
patients infected with M. pneumoniae were significantly
younger than those with viruses or bacteria [M. pneumoniae
CAP (years of age and age range): 32 (18–75); viral CAP:
43 (18–94); bacterial CAP: 48 (18–84), P < 0.05]. Expec-
toration was more common in bacterial CAP patients
compared with the other two groups [bacterial CAP:
93.9% (31/33), viral CAP 73.0% (89/122), M. pneumoniae
CAP: 69.4% (34/49), P < 0.05]. Dyspnea was significantly
different between viral and bacterial CAP [23.8% (29/122)
vs. 6.1% (2/33), P < 0.05] but not in the comparison be-

































Figure 1 Pathogen distribution. (V, virus; M, mycoplasma pneumoniae; B, bacteria; +, mixed).
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(2/33), P > 0.05], or M. pneumoniae and virus [12.2% (6/49)
vs. 23.8% (29/122), P > 0.05]. Other characteristics were
not statistically significantly different.
Predictive diagnostic model of viral CAP
We performed univariate logistic analysis of all variables
in Tables 1, 2, and 3 for viral CAP and selected the
following variables with P < 0.2 for multivariate logistic re-
gression analysis: coexisting disease, cough, expectoration,
dyspnea, chest pain, dry rales and WBC counts (Table 4).
The multivariate logistic analysis identified four independ-
ent factors with P < 0.1 associated with viral CAP, namely
cough (OR 2.40, P < 0.1), dyspnea (OR 2.20, P < 0.05),
chest pain (OR 0.54, P < 0.1) and WBC counts (OR 0.93,
Table 1 Demographic factors of patients in different groups
Groups
V(n = 122) M(n = 49) B(n = 33) MIX(n = 67) N(n = 229) P
Male sex (%) 74(60.7) 26(53.1) 25(75.8) 45(67.2) 120(52.4) >0.05
Age (years) 43(18–94) 32(18–75) 48(18–84) 33(18–80) 47(18–86) <0.05
18-44 63(51.6) 38(77.6) 14(42.4) 47(70.1) 110(48.0) >0.05
45-59 25(20.5) 6(12.2) 11(33.3) 6(9.0) 46(20.0) >0.05
≥60 34(27.9) 5(10.2) 8(24.2) 14(20.9) 73(31.9) >0.05
Smoking (%) 30(24.6) 10(20.4) 13(39.4) 13(19.4) 56(24.5) >0.05
Coexisting disease (%) 17(13.9) 5(10.2) 4(12.1) 5(7.5) 47(20.5) >0.05
Tumor (%) 3(2.5) 1(2.0) 0(0.0) 0(0.0) 3(1.3) >0.05
Coronary heart disease (%) 7(5.7) 3(6.1) 3(9.1) 2(3.0) 20(8.7) >0.05
Cardiac insufficiency (%) 2(1.6) 0(0.0) 0(0.0) 0(0.0) 5(2.2) >0.05
Cerebrovascular disease (%) 5(4.1) 1(2.0) 2(6.1) 2(3.0) 11(4.8) >0.05
Chronic nephropathy (%) 1(0.8) 1(2.0) 0(0.0) 0(0.0) 6(2.6) >0.05
Chronic hepatopathy (%) 1(0.8) 0(0.0) 0(0.0) 0(0.0) 3(1.3) >0.05
Diabetes mellitus (%) 4(3.2) 2(4.1) 1(3.0) 2(3.0) 21(9.2) >0.05
CAP hospitalization within 1year (%) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 2(0.9) >0.05
COPD* (%) 4(3.2) 0(0.0) 0(0.0) 1(1.5) 3(1.3) >0.05
Autoimmune disease (%) 1(0.8) 0(0.0) 0(0.0) 0(0.0) 0(0.0) >0.05
Antibiotic pretreatment (%) 75(61.5) 35(71.4) 24(72.7) 42(62.7) 147(64.1) >0.05
Notes: V: single viral infection; M: single mycoplasma pneumoniae infection; B: single bacterial infection; MIX: mixed infections; N: no pathogen detected.*COPD,
chronic obstructive pulmonary disease.
Table 2 Symptoms and clinical signs of patients in different groups
Groups
V(n = 122) M(n = 49) B(n = 33) MIX(n = 67) N(n = 229) P
Fever (%) 110(90.2) 48(98.0) 31(94.0) 60(89.6) 198(86.5) >0.05
Body temperature (°C) 37.6 ± 0.9 37.7 ± 1.0 37.6 ± 1.1 37.7 ± 1.0 37.6 ± 0.9 >0.05
Max temperature (°C) 38.9 ± 0.7 39.2 ± 0.6 39.2 ± 0.8 39.0 ± 0.8 38.8 ± 2.2 >0.05
Heart rate (beats/minute) 85.9 ± 13.8 91.5 ± 15.3 86.4 ± 13.0 88.4 ± 14.5 85.8 ± 12.3 >0.05
Respiratory rate (breaths/minute) 19.8 ± 2.4 19.5 ± 2.3 20.2 ± 3.5 19.7 ± 2.0 19.9 ± 2.7 >0.05
Systolic pressure≤ 90 mmHg (%) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 1(0.4) >0.05
Cough (%) 117(96.0) 46(93.8) 33(100.0) 66(98.5) 208(90.8) >0.05
Expectoration (%) 89(73.0) 34(69.4) 31(93.9) 61(91.0) 154(67.2) <0.05
Dyspnea (%) 29(23.8) 6(12.2) 2(6.1) 10(14.9) 32(13.9) <0.05
Chest pain (%) 13(10.7) 9(18.4) 3(9.1) 2(3.0) 29(12.7) >0.05
Diarrhea and (or) vomiting (%) 10(8.2) 9(18.4) 4(12.1) 4(6.0) 18(7.9) >0.05
Dizziness and (or) headache (%) 20(16.4) 9(18.4) 4(12.1) 8(12.0) 36(15.7) >0.05
Moist rales (%) 46(37.7) 21(42.9) 20(60.6) 31(46.3) 90(39.3) >0.05
Dry rales (%) 13(10.6) 5(10.2) 3(9.1) 11(16.4) 18(7.9) >0.05
Notes: V: single viral infection; M: single mycoplasma pneumoniae infection; B: single bacterial infection; MIX: mixed infections.
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P < 0.05) (Table 5). Subsequently, discriminatory analysis
and ROC curves were used to establish and assess predict-
ive diagnostic models of CAP by using these four inde-
pendent factors. The predictive diagnostic model of viral
CAP included cough, dyspnea, absence of chest pain and
WBC count (4.0-10.0) × 109/L, with an area under the
ROC curve (AUC) of 0.61 (95% CI: 0.55 to 0.68). The sen-
sitivity and specificity of this model were 37.4% (95% CI:
29.1% to 45.7%) and 77.2% (95% CI: 71.5% to 82.9%), re-
spectively (P < 0.05).
Predictive dagnostic model of M. pneumoniae CAP
Univariate logistic analysis was performed with all vari-
ables in Tables 1, 2, and 3 for M. pneumoniae CAP, and
the following variables with P < 0.2 were selected for
multivariate logistic regression analysis: age, coexisting
disease, smoking, fever, max temperature, neutrophil and
C-reactive protein (Table 4). Through the multivariate
logistic analysis, two independent factors with P < 0.1
associated with M. pneumoniae CAP were identified,
namely age (OR 0.94, P < 0.05) and coexisting disease
(OR 0.33, P < 0.1) (Table 5). Subsequently, discriminatory
analysis and ROC curves were used to establish and assess
a predictive diagnostic model of CAP with these two in-
dependent factors. The predictive diagnostic model of
M. pneumoniae CAP included the characteristics of being
younger than 45 years of age and not having a coexisting
disease, with an AUC of 0.61 (95% CI: 0.53 to 0.69). The
sensitivity and specificity of this model were 54.9% (95% CI:
51.2% to 64.8%) and 58.0% (95% CI: 43.4% to 66.5%),
respectively (P < 0.05).
Discussion
In this study, at least one pathogen was found in 54.2%
of the patients, and viruses accounted for most of the
Table 3 Laboratory test results of patients in different groups
Groups
V(n = 122) M(n = 49) B(n = 33) MIX(n = 67) N(n = 229) P
WBC counts (×109/L) 7.9 ± 3.5 8.4 ± 3.7 7.5 ± 3.4 7.5 ± 3.5 8.7 ± 4.1 >0.05
<4.0 (%) 7(5.7) 5(10.2) 4(12.1) 6(9.0) 12(5.2) >0.05
4.0 ~ 10.0 (%) 90(73.8) 31(63.3) 24(72.7) 51(76.1) 151(65.9) >0.05
>10.0 (%) 25(20.5) 13(26.5) 5(15.2) 10(14.9) 66(28.8) >0.05
Neutrophil (%) 70.6 ± 12.2 70.1 ± 11.0 71.3 ± 13.5 69.0 ± 13.9 69.7 ± 14.5 >0.05
Lymphocyte (%) 20.3 ± 9.8 20.1 ± 8.3 20.5 ± 11.2 21.2 ± 9.9 21.3 ± 11.6 >0.05
Hematocrit (%) 40.9 ± 6.7 39.9 ± 3.9 40.5 ± 5.1 39.3 ± 4.7 40.3 ± 21.7 >0.05
Platelets (×109/L) 209.7 ± 76.8 206.6 ± 65.4 194.6 ± 80.4 202.7 ± 68.0 218.3 ± 66.9 >0.05
Alanine aminotransferase (U/L) 28 ± 22.8 25.0 ± 15.0 45.1 ± 57.0 25.9 ± 20.6 29.3 ± 31.0 >0.05
Aspartate aminotransferase (U/L) 28.3 ± 16.5 26.1 ± 13.1 37.7 ± 37.4 29.4 ± 48.6 26.5 ± 20.1 >0.05
Blood creatinine (μmol/L) 68.7 ± 22.9 64.3 ± 19.5 65.7 ± 14.8 59.8 ± 17.2 66.3 ± 48.3 >0.05
Blood sodium (mmol/L) 137.6 ± 3.7 137.5 ± 4.2 137.8 ± 3 138.0 ± 3.3 138.5 ± 3.4 >0.05
pH 7.4 ± 0.0 7.4 ± 0.0 7.4 ± 0.0 7.4 ± 0.0 7.4 ± 0.1 >0.05
PaO2 (mmHg) 80.3 ± 14.9 79.5 ± 17.6 85.5 ± 50.1 85.2 ± 17.8 82.8 ± 19.8 >0.05
ESR1 (mm) 34.7 ± 26.1 39.7 ± 21.6 43.5 ± 26.4 39.2 ± 23.9 40.9 ± 28.4 >0.05
C-reactive protein (mg/L) 50.7 ± 60 52 ± 42.8 67.5 ± 56.6 58.8 ± 92.2 62.9 ± 61.7 >0.05
Prothrombin time (s) 12.3 ± 2.2 12.5 ± 1.3 12.7 ± 1.7 12.3 ± 1.6 12.7 ± 3.7 >0.05
APTT2(s) 35.8 ± 9.3 35.7 ± 9.5 29.7 ± 6.7 33.1 ± 14.3 32.8 ± 5.7 >0.05
Notes: V: single viral infection; M: single mycoplasma pneumoniae infection; B: single bacterial infection; MIX: mixed infections; N: no pathogen detected. 1ESR,
erythrocyte sedimentation rate; 2APTT, activated partial thromboplastin time.
Table 4 Univariate analysis of clinical factors of patients
with viral and mycoplasma pneumoniae CAP (P < 0.2)
Variables Odds ratio (95% CI) P
Viral CAP
Coexisting disease 0.64 0.38 1.09 0.103
Cough 2.87 1.08 7.67 0.035
Expectoration 1.47 0.95 2.25 0.081
Dyspnea 1.94 1.19 3.15 0.008
Chest pain 0.61 0.32 1.13 0.113
Dry rales 1.54 0.85 2.77 0.152
WBC counts 0.95 0.91 1.00 0.067
Mycoplasma pneumoniae CAP
Age 0.96 0.95 0.98 <0.001
Coexisting disease 0.34 0.14 0.80 0.013
Smoking 0.60 0.34 1.08 0.089
Fever 2.70 0.95 7.71 0.063
Max temperature 1.58 1.13 2.20 0.007
Neutrophil 0.99 0.97 1.00 0.121
C-reactive protein 1.00 0.99 1.00 0.078
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cases (36.4%). These results are consistent with previous
studies reporting that etiological evidence can be obtained
for about half of adult CAP cases, with viruses being as-
sociated with about a third [14-16]. Available large-scale
epidemiological investigations of adult viral CAP have
mainly been conducted in developed countries. In China,
Cao et al. [17] found that the most common pathogen
was M. pneumoniae (29.4%), and respiratory viruses were
the second most prevalent (9.6%) in 197 outpatients with
CAP. In this study, with a larger sample size, we found a
greater proportion of virus-associated CAP. Previously,
the incidence of CAP due to atypical pathogens from
4,337 patients worldwide between September 1996 to
April 2004 was found to be 22% [18]. Another multicenter
study on pathogenic agents in 665 adult patients with
CAP in China between December 2003 to November
2004 showed that M. pneumoniae was the most common
type of pathogen (20.7%) [19]. Bao et al. also found
M. pneumoniae as the top etiological pathogens among
402 fever outpatients with CAP in China from January
2007 to January 2008 [20]. In our study, M. pneumoniae
was the second most prevalent etiologic agent at 18%, indi-
cating that attention should still be paid to M. pneumoniae
infections in adult CAP outpatients in China. In the last
decade, changes in the prevalence of etiological agents of
CAP have been observed, such as the decreasing inci-
dence of bacterial CAP and increasing trends in atypical
respiratory pathogens and respiratory viruses [21,22].
These changes may be accounted in part by the emer-
gence of PCR technology, either in single or multiplex
format, which has greatly improved the sensitivity of
diagnostic tests for respiratory viruses (e.g., influenza virus,
parainfluenza virus, adenovirus), especially for those that
are hard to culture, such as rhinoviruses, coronaviruses and
metapneumoviruses [23-25]. Another explanation for the
observed changes in CAP-related pathogens is that the
use of oral antibiotics by patients at the beginning of
the febrile episode can significantly reduce the sensitivity
of culture [16,26]. As only about 11% of patients with
CAP will usually have positive blood cultures, which are
more commonly associated with severe illness [27], it is
difficult to obtain a positive blood culture in mild to
moderate cases of CAP. In our study, two-thirds of the
study patients were previously treated with antibiotics,
which significantly limited the sensitivity and specificity
of detection.
Mixed infections have been reported in many previous
studies [28-30]. In our current investigation, 13.4% of study
patients had mixed infections. However, interactions be-
tween different pathogens in vivo are poorly understood.
It is unclear whether a virus alone causes pneumonia or
acts in conjunction with other respiratory pathogens, and
a favored hypothesis is that a viral infection is followed by
a secondary bacterial infection [9,31-33].
In this study, we detected 15 types of respiratory viruses
and analyzed their distribution to supplement the epi-
demiological investigations of adult viral CAP in China.
Consistent with previous studies [9,30], we have shown
that Flu A was the most commonly detected virus associ-
ated with CAP and have drawn attention to this particular
pathogen as a cause of pneumonia, especially in the win-
ter. Rhinovirus infections, which are usually limited to the
upper respiratory tract but also can cause pneumonia [34],
ranked second. The virus distribution in our study was
similar to that in previous reports [35-37].
A major current challenge for determining etiological
pathogens of adult CAP centers on making the diagnosis
based on patient clinical features [38]. In our study, by com-
parison of monoinfections, we found that M. pneumoniae
CAP patients were significantly younger than viral or bac-
terial CAP patients. Cough with expectoration was more
common in bacterial CAP patients compared with the
other two groups, and dyspnea was significantly different
between individuals with viral and bacterial CAP. Similar
conclusions have been made in previous reports, yet the
results differed among different study populations [39,40].
Therefore, exploring etiological diagnostic models based
on combinations of clinical factors in order to identify
the causative pathogens has been a focus of CAP research.
While diagnostic models of bacterial CAP have been
established [41-43], data for such predictive models for
viral and M. pneumoniae CAP are still lacking. In our
study, we attempted to build viral and M. pneumoniae
diagnostic models based on combinations of clinical
characteristics from a study population in China. Fac-
tors for the predictive etiological diagnostic model of viral
CAP consisted of cough, dyspnea, mild chest pain and WBC
counts (4.0 -10.0) × 109/L, and that for M. pneumoniae
CAP included being younger than 45years old and the
absence of a coexisting disease. Corresponding predic-
tors for each model have been reported in the literature.
For example, Yang et al. [44] described the association
of cough with Flu A infection. Johnstone et al. [40]
reported that a viral infection was usually accompanied
Table 5 Predictive diagnostic model factors of viral and
mycoplasma pneumoniae CAP (P < 0.1)
Variables Odds ratio (95% CI) P
Viral CAP
Cough 2.40 0.89 6.52 0.085
Dyspnea 2.20 1.31 3.68 0.003
Chestpain 0.54 0.28 1.03 0.061
WBC counts 0.93 0.88 0.99 0.015
Mycoplasma pneumoniae CAP
Age 0.94 0.92 0.97 <0.001
Coexisting disease 0.33 0.09 1.21 0.094
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by the absence of chest pain and a normal leukocyte
count. Ma et al. found that independent predictors of
viral pneumonia included nursing home residence and
absence of leukocytosis [45]. Meanwhile, Cao et al. [17]
reported that M. pneumoniae infection was most com-
mon in young pneumonia patients without a coexisting
disease. In our study, we combined these clinical char-
acteristics to build the diagnostic models. From the AUC
of these models, we can see that with the use of clinical
characteristics alone, it would be difficult to determine the
causative agent(s) accurately, but they can provide a pre-
liminary etiological diagnosis for CAP patients before
laboratory results are available. As the accuracy of CAP
etiological diagnostic models may be dependent on treat-
ment type (inpatient or outpatient), age and the number
of patient samples [41-43], the specificity and sensitivity
of such models need to be further studied. Currently,
etiological diagnosis of CAP still depends on laboratory
pathogen test results.
While the data obtained was informative, this study
had several limitations. One was that we did not investi-
gate the pathogen prevalence in asymptomatic adults
from the same population. However, Lieberman et al.
had previously found a significantly lower proportion of
respiratory viruses in asymptomatic control subjects
(7.1%) than in CAP patients [31.7% with at least one re-
spiratory virus, including influenza virus (4.4% vs. 0.4%
in control) and rhinovirus (4.9% vs. 2.0% in control]
[15]. Second, we used different assays (multiplex PCR,
quantitative real-time fluorescence PCR, culture and S.
pneumoniae urinary antigen immunoassay) for different
pathogens but did not compare the differences in sensi-
tivity and specificity between these microbiological
techniques. Third, two-thirds of study patients self-
medicated with antibiotics, which significantly limited the
sensitivity and specificity of bacterial detection assays.
Fourth, microbiological analysis was not performed for cer-
tain respiratory pathogens, such as Chlamydia pneumoniae,
Legionella pneumophila and Mycobacterium tuberculosis.
Fifth, as the individuals in this population were not se-
verely ill, the findings of this study may not be general-
ized to hospitalized or severely ill CAP patients. Sixth,
the data collection was limited to one year, and the
number of study patients may have been insufficient to
draw firm conclusions. Therefore, further studies with a
larger sample size will be needed to confirm and extend
our findings.
Conclusions
In this study, the distribution of CAP-associated pathogens
in adults was consistent with trends from other etiological
studies showing that bacterial CAP is decreasing, while
CAP-associated respiratory viruses and M. pneumoniae are
increasing. The results indicate that potential viral and
M. pneumoniae infections should be given more atten-
tion in adult CAP outpatients. Our survey of 15 types of
respiratory viruses and analysis of the distribution viruses
supplement the epidemiological investigations of adult
viral CAP in China. Among the virus strains detected,
Flu A virus was found to be the most prevalent from
November 2010 to March 2011, emphasizing the im-
portance of this virus in the winter. As identifying the
potential causative pathogens of CAP is of major clinical
value, we also made progress on building viral and
M. pneumoniae diagnostic models based on combina-
tions of clinical characteristics. These two models revealed
that it would be difficult to arrive at the diagnosis accur-
ately using clinical characteristics alone, but they can pro-
vide a preliminary indication of the etiological pathogen(s)
before laboratory results become available. At the same
time, our results highlight the fact that it is necessary to
conduct pathological examinations not only for bacteria
but also for viruses and M. pneumoniae for etiological
diagnosis of CAP patients.
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